What Medical Conditions Does a Breath Test Diagnose?

Breath tests are used to diagnose or monitor a surprisingly wide range of medical conditions, from common gut infections to liver disease, kidney impairment, airway inflammation, and even certain cancers in research settings. The basic principle varies by test: some measure a specific gas produced after you swallow a labeled substance, others detect the concentration of a naturally occurring compound in your exhaled air, and still others profile the complex mix of volatile organic compounds your body releases with every breath. What all of them share is that they are non-invasive, relatively fast, and increasingly accurate.

Helicobacter Pylori Infection

The urea breath test is probably the most widely recognized diagnostic breath test in medicine. It detects Helicobacter pylori, the bacterium responsible for most stomach ulcers and a major risk factor for gastric cancer. You drink a solution containing urea labeled with a carbon isotope (usually carbon-13). If H. pylori is living in your stomach lining, its urease enzyme breaks down the labeled urea, releasing labeled carbon dioxide that you then exhale. A breath sample collected about 15 to 30 minutes later measures the ratio of labeled to unlabeled CO₂, and an elevated ratio signals the bacterium’s presence.

The accuracy is high. A meta-analysis focusing on Asian populations found that the carbon-13 urea breath test had a sensitivity of about 97% and a specificity of about 96%, meaning it catches nearly all true infections and rarely flags someone who is not infected.¹ Broader meta-analyses also support the test’s high diagnostic accuracy, though study-to-study variation exists depending on the dose used and when the breath sample is collected.² Clinicians use this test both for initial diagnosis and to confirm that the bacterium has been eradicated after a course of antibiotics.³

One practical detail worth knowing: proton pump inhibitors (the common acid-reducing medications) can suppress H. pylori activity enough to produce a false negative. Doctors typically ask you to stop those drugs for a couple of weeks before the test. Antibiotics taken recently can also interfere. If you have been told to do a urea breath test, ask about any medications you should pause beforehand.

Small Intestinal Bacterial Overgrowth and Methane Overgrowth

Hydrogen and methane breath tests are the standard way to check for small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO). You fast overnight, then drink a sugar solution, usually glucose or lactulose. Bacteria that have colonized the small intestine ferment the sugar before it reaches the colon, producing hydrogen gas that enters the bloodstream and is exhaled through the lungs. Methane-producing organisms (archaea, not technically bacteria) produce methane by a similar route. A series of breath samples over two to three hours tracks how quickly and how much of each gas appears.

Breath testing is the most widely used method for diagnosing SIBO, and for IMO it is essentially the only practical diagnostic tool available in clinical settings.⁴ While small bowel aspiration (threading a tube into the intestine and culturing the fluid) is sometimes called the gold standard, it is invasive and not routinely done. Breath tests comparing favorably with aspirate culture have been described as sufficiently sensitive and highly specific for SIBO diagnosis.⁵

Researchers have also explored whether a single rapid breath measurement of both methane and hydrogen, rather than the extended multi-sample protocol, could work as a quicker screen. Early results suggest that fasting methane above a certain threshold, or specific combinations of methane and hydrogen levels, may be viable for diagnosis.⁶ That could eventually shorten what is now a fairly time-consuming test.

Carbohydrate Malabsorption

The hydrogen breath test is also the go-to method for diagnosing lactose malabsorption, fructose malabsorption, and sorbitol malabsorption. The principle is the same as with SIBO testing: you drink a solution of the suspect sugar, and if your small intestine cannot absorb it properly, bacteria in the colon ferment whatever passes through, producing hydrogen that shows up in your breath. A significant rise in breath hydrogen after ingesting lactose, for instance, indicates lactose malabsorption.⁷

Worth noting: malabsorption and intolerance are not the same thing. You can malabsorb lactose (the breath test will be positive) without having symptoms. Intolerance means the malabsorption is actually causing bloating, cramps, or diarrhea. The breath test tells you about malabsorption. Connecting that result to your symptoms is a clinical judgment your doctor makes alongside the test data.

Methane and Constipation-Predominant IBS

Methane detected during a breath test has a specific clinical connection to constipation. People with constipation-predominant irritable bowel syndrome (IBS-C) tend to produce more methane on breath testing than people with diarrhea-predominant IBS, and this links back to higher levels of a particular gut organism called Methanobrevibacter smithii.⁸ The amount of methane in breath correlates strongly with both the absolute quantity and the proportion of M. smithii in stool.⁹ Higher M. smithii counts also correlate with lower stool frequency.¹⁰

This matters practically because methane itself appears to slow gut transit. A breath test showing elevated methane can help a gastroenterologist subtype your IBS and guide treatment, including therapies that target methane-producing organisms specifically. It is one of the clearer examples of a breath test result that directly influences treatment choices.

Airway Inflammation and Asthma

Fractional exhaled nitric oxide (FeNO) testing is a different kind of breath test entirely. Instead of swallowing a substrate, you simply breathe into a handheld device that measures nitric oxide levels in your exhaled air. Elevated FeNO indicates a particular type of airway inflammation driven by the immune system’s eosinophilic response, which is characteristic of allergic or “type 2” asthma.

Clinical guidelines now recommend FeNO as an add-on to the standard evaluation when asthma is suspected.¹¹ A high FeNO reading can also predict whether a patient is likely to respond to inhaled corticosteroids, help monitor whether those medications are actually controlling the inflammation, and flag non-adherence (if FeNO climbs again after treatment, you might not be taking your inhaler consistently). Higher FeNO levels have been associated with lower lung function and a greater risk of future asthma flare-ups, especially when combined with other clinical measures.¹²

FeNO does have limits. Its sensitivity is not great at ruling asthma out, so a normal reading does not necessarily mean you don’t have asthma. It is better understood as a marker of one specific kind of inflammation than a standalone diagnostic. In a chart review of patients with asthma, COPD, or an overlap of both, FeNO testing changed the diagnosis in a meaningful proportion of cases, shifting some patients from a COPD diagnosis to asthma or overlap.¹³ Getting that distinction right matters because the treatments differ.

Liver Function

The carbon-13 methacetin breath test evaluates how well your liver is metabolizing drugs. You take a small dose of methacetin, a compound processed by a specific liver enzyme (part of the cytochrome P450 system). The liver converts methacetin into a product that releases labeled CO₂, which you exhale. How quickly and how much labeled CO₂ appears in your breath reflects the functional capacity of that enzyme pathway.¹⁴

This test has been studied for decades as a way to diagnose cirrhosis, gauge how severe liver disease is, and predict outcomes in patients being evaluated for liver surgery or transplant.¹⁵ Despite promising evidence, adoption has remained limited, partly because different research groups have used different protocols and cutoff values. Standardization efforts are ongoing, and the test remains more common in research centers and specialized hepatology clinics than in everyday practice.

Gastric Emptying and Motility Disorders

The carbon-13 octanoic acid breath test measures how fast your stomach empties solid food, which is useful for diagnosing gastroparesis (delayed stomach emptying) and monitoring how well motility-related treatments are working. You eat a test meal containing a labeled fatty acid. As the meal empties from the stomach into the small intestine, the label is absorbed and metabolized, and labeled CO₂ appears in your breath. Delayed appearance means delayed emptying.

Studies in people with diabetes, a population especially prone to gastroparesis, have shown that this breath test can reliably identify normal versus delayed gastric emptying.¹⁶ Recent work has also tested the method in patients who have had bariatric surgery, where anatomy is altered. A proof-of-concept analysis found acceptable agreement between the breath test and the traditional scintigraphy method (which involves imaging a radioactive meal) after both sleeve gastrectomy and gastric bypass.¹⁷ The appeal is clear: no radiation exposure and something that could eventually be done in a regular office rather than a nuclear medicine department.

Pancreatic Exocrine Insufficiency

When the pancreas does not produce enough digestive enzymes, fat digestion suffers. The carbon-13 mixed triglyceride breath test picks this up. You eat a test meal containing labeled triglycerides. If your pancreas releases enough lipase to break them down normally, labeled CO₂ appears in your breath on schedule. Low or delayed appearance points to pancreatic exocrine insufficiency, a common complication of chronic pancreatitis and other pancreatic diseases.¹⁸

This breath test is also useful for monitoring whether enzyme replacement therapy is actually restoring normal fat digestion, which matters because poor fat absorption leads to nutritional deficiencies and weight loss. Modified versions of the test can detect even moderate insufficiency, not just the severe cases that are obvious clinically.¹⁹

Chronic Kidney Disease

When the kidneys lose their ability to clear waste products, urea accumulates in the blood and breaks down into ammonia, some of which is exhaled. Measuring breath ammonia can serve as a marker of kidney impairment. In studies comparing breath ammonia to standard blood measures of kidney function, ammonia levels correlated strongly with serum creatinine and estimated kidney filtration rate. Patients with chronic kidney disease had breath ammonia levels roughly seven times higher than controls.²⁰

A more recent study refined the approach and found that when patients fasted before the test, diagnostic accuracy improved substantially, with sensitivity and specificity both above 87%.²¹ This is still largely a research tool, but the idea of a quick, non-invasive screen for kidney impairment is attractive for settings where blood tests are not readily available, or as a way to reduce the frequency of blood draws in patients already being monitored.

Metabolic Monitoring Through Breath Acetone

Your body produces acetone when it breaks down fat, and that acetone shows up in exhaled breath. In healthy people eating a normal diet, breath acetone sits around 1 part per million. In someone with uncontrolled diabetes experiencing ketoacidosis, it can soar to over 1,000 ppm.²² That extreme elevation is what gives the characteristic “fruity breath” smell that clinicians have recognized for centuries.

Research has established that breath acetone correlates with blood ketone levels across different metabolic states, including normal blood sugar, prediabetes, and diabetes.²³ The correlation is strongest in people with diabetes, which is the group where monitoring matters most.²⁴ The potential application is a non-invasive way to screen for or monitor ketosis without blood draws or urine strips. Consumer devices claiming to measure breath acetone for ketogenic dieters already exist, but their accuracy varies and they are not yet a replacement for medical-grade monitoring.

Lung Cancer and Other Cancers

One of the most actively researched frontiers in breath testing is cancer detection. The idea is that tumors alter cellular metabolism, producing a distinct profile of volatile organic compounds (VOCs) that can be detected in exhaled breath. Lung cancer has received the most attention. In one prospective study involving patients with lung cancer and healthy controls, a diagnostic model based on 16 breath VOCs (including aldehydes, hydrocarbons, and ketones) achieved roughly 89% sensitivity and 89% specificity in an external validation group.²⁵

Another study found that a breath-based VOC analysis performed comparably to PET-CT scanning for distinguishing lung cancer from benign lung nodules, which is a common diagnostic dilemma in clinical practice.²⁶ Research into the specific volatile compounds associated with lung cancer, and the metabolic pathways that produce them, continues to build the evidence base.²⁷ Still, this is not yet a tool your doctor can order in routine practice. The technology, validation, and standardization are not there yet for widespread screening. But the research is real and advancing faster than many people realize.

Respiratory Disease Profiling Through Exhaled Condensate

Beyond specific gas measurements, a technique called exhaled breath condensate (EBC) collection captures the tiny droplets of fluid that come out with every breath. This condensate contains biomarkers of inflammation and oxidative stress that can be measured in a lab. Researchers have studied EBC for profiling chronic inflammatory and neoplastic diseases of the respiratory tract, including asthma, COPD, and lung cancer.²⁸ For COPD specifically, exhaled breath condensate provides a non-invasive way to sample the airways and measure markers of the airway inflammation and oxidative stress driving the disease.²⁹ Like cancer breathomics, this remains primarily a research tool rather than something in standard clinical workflows.

Infectious Disease Screening

The COVID-19 pandemic accelerated interest in breath-based infection detection. Several research groups developed systems that analyze the pattern of volatile compounds in exhaled breath to distinguish infected from uninfected individuals. One pilot study using ion mobility spectrometry on nasal breath was able to correctly classify patients with SARS-CoV-2 infection and those with influenza A from uninfected controls, correctly sorting nearly all participants in cross-validation.³⁰ Another trial using mass spectrometry and machine learning on exhaled breath reported roughly 95% accuracy in identifying COVID-19 cases, comparable to PCR and antigen testing.³¹

Beyond COVID, portable electronic nose (e-nose) devices have been tested for tuberculosis screening. One study with a handheld point-of-care e-nose found sensitivity around 88% and specificity around 92% for distinguishing TB patients from healthy individuals.³² For a disease that typically requires sputum cultures or molecular testing, a quick breath-based screen could be transformative in remote areas and overcrowded clinical settings. These devices are not yet in widespread clinical use, but the diagnostic performance in published studies is encouraging.

Occupational Exposure Monitoring

Breath testing also has a role outside of disease diagnosis per se. In occupational health, measuring chemicals in exhaled breath can reveal workplace exposures. Benzene, a known carcinogen, is one well-studied example. Measuring benzene concentration in exhaled air collected eight hours after exposure has been validated as a biomarker for occupational exposure, even at low airborne concentrations. The detection limit is roughly 1/200th of the biological exposure index recommended by occupational health authorities.³³ This approach avoids the need for blood sampling and can be applied to both occupationally exposed and non-exposed groups, including separating the signal of workplace exposure from the background benzene load of smoking.

Electronic Noses and the Broader Sensor Landscape

Running through many of these applications is an emerging class of technology: electronic noses. These devices use arrays of chemical sensors to detect patterns in the volatile compounds present in a breath sample. Rather than identifying a single gas, they recognize a “breathprint” associated with a particular condition. Advances in e-nose design are providing the potential for new noninvasive tools that could be used for point-of-care diagnosis across a range of diseases and metabolic disorders.³⁴

The challenge, as with most of the newer breath-based diagnostics, is standardization. A breath sample is sensitive to what you ate, when you last brushed your teeth, ambient air quality, and a dozen other variables. The tests that are already in routine clinical use, like the urea breath test for H. pylori and FeNO for asthma, succeeded precisely because researchers figured out how to control those variables and agreed on reliable cutoff values. The newer VOC-based cancer screens, kidney disease markers, and infection detectors are still working through that process. The science is genuine and in many cases quite strong, but the path from a promising pilot study to a test your doctor can order at a routine visit is long and depends on nailing down protocols that different labs and clinics can reproduce reliably.